Validation of a Risk Prediction Model for Multidrug-Resistant Gram-Negative Bacteria Infection in Adult ICU Patients A Multicenter Real-World Prospective Study

What this Trial Is About

This research aims to validate a previously developed risk prediction model for multidrug-resistant Gram-negative bacterial MDRGNB infections in adult patients admitted to intensive care units ICUs. The multicenter prospective study includes adult ICU patients from 11 different research centers, focusing on predicting MDRGNB infection risk shortly after ICU admission using commonly available clinical data. The study enrolls patients consecutively and generates infection risk predictions within 24 hours of ICU admission without influencing clinical decisions. The prediction models performance is assessed in real-world settings by evaluating its discrimination, calibration, and clinical net benefit using a predefined risk threshold. The study is observational and does not involve any investigational treatments or interventions. Participants undergo routine clinical monitoring, including collecting clinical microbiological specimens within 48 hours of ICU admission. Researchers track the primary outcome of MDRGNB infection occurring within 48 hours after admission. Secondary outcomes include 28-day mortality, organ failure assessment scores at 48 hours, and any antibiotic-related adverse events within 28 days. The study follows patients over this period to assess outcomes without altering standard care.

Multicenter Validation of a Risk Prediction Model for MDRGNB Infection